Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Protocol-driven versus intensive treat-to-target allopurinol dose escalation for gout
ACTRN12622001279718Phase 4Recruiting
- Sponsor
- University of Otago
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of allopurinol in gout (2 arms), sponsored by University of Otago. Primary endpoint: Proportion of participants with serum urate below 0.36 mmol/L. Started Feb 2023; status: recruiting.
02
Drugs
allopurinol
03
Conditions
gout
Beyond the preview
Go deeper on ACTRN12622001279718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622001279718.